Venus Remedies launches 'Elores' in India

Venus Remedies Ltd has launched CSE 1034 under the brand name "ELORES". It is a novel Antibiotic Adjuvant Entity (AAE) to combat antimicrobial resistance caused by MDR, ESBL producing strains.

ELORES is designed specifically to target growing bacterial resistance mechanisms and has a unique profile of action which gives it an edge over all the existing therapies. This unique antibiotics adjuvant entity creates a synergistic effect due to its activity on AMRINGER (Acquired Multiple Resistance in Gram Negative Enterococci and Rods) which stops development and spread of bacterial resistance.

This product is effective against Metallo betalactamases (MBL) producing pathogens which are not susceptible to most of the existing antibiotics. It is also unique in its way that it not only kills resistant pathogens (Bacteria) but also prevents the spread of resistance.

The Venus Remedies Ltd stock was trading at Rs.279.30, up by Rs.4.90 or 1.79%. The stock hit an intraday high of Rs.285 and low of Rs.274.15.

The total traded quantity was 14586 compared to 2 week average of 7361.

Source : Equity Bulls

Keywords